Using Skindex-29 Scale to Assess The Impact of Androgenetic/Patterned Hair Loss on Quality of Life of Patients in Pakistan

Sakina Sadiq Malik, Tehseen Naveed*, Safoora Naveed**, Irfan Jamil Minhas***, Bushra Muzaffar Khan****, Suniya Sadiq*****

Combined Military Hospital /National University of Medical Sciences (NUMS) Rawalpindi Pakistan, *Combined Military Hospital Lahore/National University of Medical Sciences (NUMS) Pakistan, **Army Medical College/National University of Medical Sciences (NUMS) Rawalpindi Pakistan, ***Field Hospital Karachi Pakistan, ****Headquarters Log 4 Corp, Pakistan

ABSTRACT

Objective: to assess the impact of androgenetic alopecia (AGA)/female patterned hair loss (FPHL) on the quality of life of Pakistani patients using Skindex-29 scale.

Study Design: Cross-sectional study.

Place and Duration of Study: Outpatient Department of Dermatology, Combined Military Hospital, Lahore Pakistan, from Oct 2020 to Mar 2021.

Methodology: Three hundred patients (150 males and 150 females) having androgenetic alopecia (AGA)/female patterned hair loss (FPHL) were selected by consecutive sampling. Skindex-19 questionnaire was used to assess the impact of alopecia on their quality of life.

Results: Mean age of study participants was 41.6 ± 12.4 years (range: 18-72 years). Maximum patients (40.7%) had grade-I severity of alopecia. Most of the patients (37.3%) had disease duration of 1-5 years. Mean global score, symptoms scale score, emotion scale score and function scale score were 31.3 ± 14.8, 22 ± 22.56, 41.67 ± 28.1 and 30 ± 26.5 respectively. Gender and disease duration were statistically significant (p=0.001 and p=0.013 respectively).

Conclusion: Skindex-29 can be successfully used in our setup for quality of life studies in AGA/FPHL patients. Females were more severely affected than males as per global scores on Skindex-29.

Keywords: Androgenetic alopecia, Hair specific skindex-29, Quality of life.

How to Cite This Article: Malik SS, Naveed T, Naveed S, Minhas IJ, Khan BM, Sadiq S. Using Skindex-29 Scale to Assess the Impact of Androgenetic/Patterned Hair Loss on Quality of Life of Patients in Pakistan. Pak Armed Forces Med J 2022; 72(1): 42-46. DOI: https://doi.org/10.51253/pafmj.v72i1.6701

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

INTRODUCTION

World Health Organization defines the quality of life (QOL) as “the individuals’ perception of their position in life, in the context of the cultural and value system in which they live and concerning their goals, expectations, standards and concerns.” Health-related QOL (HRQOL) includes physical, psychological, and social health factors. A QOL scale used in dermatology is Skindex-29 scale, which was initially developed by Chren et al. This questionnaire covered three dimensions. That includes symptoms (7 items), functional impact (12 items) and effect on emotions (10 items). This scale was modified for the patients with alopecia by replacing the words ‘skin’ and ‘skin condition’ in the original Skindex-29 with ‘scalp’ or ‘alopecia,’ respectively and was renamed as the Hair Specific Skindex-29.

Androgenetic alopecia (AGA) is considered the most common type of baldness that affects roughly 50% of men and perhaps as many women older than 40 years of age. Prevalence is highest in the Caucasians. In a Chinese study, the overall prevalence of androgenetic alopecia was 21.3%, while the overall prevalence was 14.1% in a Korean study. An epidemiological study on AGA women showed the prevalence of around 19% in 1006 Caucasian patients. According to one study, 13% of premenopausal women reportedly have some evidence of androgenetic alopecia and the incidence increases in women following menopause.

AGA significantly affects the affected individuals' quality of life in both genders. Longer duration and increasing age of patients are related to more psychological distress.

This study aimed to use hair-specific Skindex-29 in our cultural context to determine the impact on QOL of AGA/FPHL. No local studies have been done using this instrument in alopecia before. This research will help our dermatologist effectively use this instrument to monitor and address the QOL in such patients.

METHODOLOGY

It was a cross-sectional study, conducted at the Outpatient Department of Dermatology in Combined
Military Hospital Lahore, from October 2020 to March 2021. Institutional Ethics Review Board permission was taken from CMH Lahore (Ref. no.238/2020 of IRC/ERB certificate dated 9/9/20).

**Inclusion Criteria:** Patients of both genders having androgenetic alopecia (AGA)/ female patterned hair loss (FPHL) were include in the study.

**Exclusion Criteria:** Patients who were already under treatment for psychiatric disorders or suffering from other skin diseases effecting the scalp like psoriasis were excluded from the study. Patients taking treatment for their alopecia in the past 3 months were also excluded from the study.

Hair-specific Skindex-29 was used, which was modified from the original Skindex-29 devised by Dr. Marry Margaret Chren. Dr. Chren was e-mailed for permission to re-use this tool in our settings. She referred us to MAPI Research trust for approval, where we submitted our request for the English version of questionnaires with ID No. 30081 and received the required permission.

Since we were validating a questionnaire, rules-of-thumb vary from 4-10 subjects per variable, with the minimum number of 100 subjects to ensure stability of the variance-covariance matrix.

We gave this questionnaire to 150 male and 150 female patients suffering from androgenetic alopecia and female patterned hair loss, respectively. Patients were selected by consecutive sampling technique based on the diagnosis confirmed by a dermatologist in our Out-Patient Department. Patients were included in the study after the informed consent.

The psychometric validation of the “hair specific” Skindex-29 (English version) questionnaire was carried out based on face validity, reliability (Cronbach α), and test-retest validity. Word “skin” was replaced with “scalp” and “skin condition” by “alopecia”, following the disease we were studying, previously done by Han et al. This Questionnaire had 29 questions related to symptoms, emotions and functional impact of alopecia. A panel of 5 dermatologists from different Pakistani hospitals were included for establishing face validity. Test-retest validity was carried out to ensure the reproducibility and reliability of the questionnaire by making 10 patients refill it one week after filling it in the first instance. Those 10 responses were used to calculate the initial Cronbach alpha, which came out 0.92, showing good internal consistency.

A dermatology resident briefed the patients about the questionnaire. Patients answered each question with a number ranging from 0-5. Answer to each item was transferred to a linear scale ranging from never=0, rarely=25, sometimes=50, often=75 and all the time=100. A score of ≥44 points was considered the severe impact on QOL as interpreted by Prinsen et al, in a study. Disease duration was categorized as less than 1 year, 1-5 years, 5-10 years and more than 10 years. Trainee dermatology checked disease severity and graded based on the Sinclair scale for FPHL and Hamilton-Norwood’s ranking for AGA. Hamilton-Norwood scale includes grades 1-7.

Statistical Package for Social Sciences (SPSS) version 21 was used for the data analysis. Reliability was be checked by Cronbach alpha. Exploratory factor analysis was done to re-check the domains covered by the questionnaire. Descriptive analysis was used for socio-demographics. The relationship of independent variables like gender, marital status, disease duration, and disease severity was analyzed and compared with the Global scores, emotion scale, function scale, and symptom scale score. Independent t-test, one way and two-way ANOVA and Spearman and Pearson correlation coefficient were used for this purpose, respectively.

**RESULTS**

Total 300 patients completed the questionnaire. There were 150 (50%) males and 150 (50%) females in the study. Minimum age of participants was 18 years and the maximum age was 72 years, with the mean age 41.6 ± 12.4 years. Mean global score was 31.31 ± 14.9 (Range: 0.69-72.42). Mean scores in symptoms, emotions and function scales were 22 ± 22.6, 41.6 ± 28.12 and 30.19 ± 26.569, respectively.

About 184 patients were married, 90 (30%) were unmarried, 10 (3.3%) were divorced and 16 (5.3%) patients were widowed. Regarding severity, 122 (40.7%) patients had grade-1, 80 (26.7%) had grade-2, 46 (15.3%) had grade-3, 35 (11.7%) had grade-4, 9 (3%) patients had grade-5, 6 (2%) patients had grade-6 and 2 (0.7%) patients had grade-7 alopecia. 84 (28%) patients had disease duration of less than 1 year, 112 (37.3%) had 1-5 years, 68 (22.7%) had disease duration of 5-10 years, 36 (12%) had the disease duration more than 10 years.

Reliability analysis of the questionnaire showed Cronbach alpha of 0.914. Cronbach alpha for questions related to three separate domains i.e., symptoms,
emotions and functions, were 0.98, 0.99 and 0.97, respectively.

Exploratory factor analysis was done by principal component analysis. The scree plot showed Eigen values of more than 1 for three components (Figure).

![Figure: Scree plot for principal component analysis of exploratory factor analysis.](image)

Varimax rotation with Keiser Normalization converged after 4 iterations yielded three domains consistent with the original domains of emotions, symptoms and functions. Independent sample t-test for gender with score of Skindex-29 showed significant relation of global score, scores in symptom and function scale with gender (Table-I).

<table>
<thead>
<tr>
<th>Score</th>
<th>Study Groups (Mean ± SD)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Male (n=150)</td>
<td>Female (n=150)</td>
</tr>
<tr>
<td>Symptoms</td>
<td>14.6 ± 17.8</td>
<td>29.5 ± 24.3</td>
</tr>
<tr>
<td>Emotions</td>
<td>38.5 ± 2.6</td>
<td>44.8 ± 1.91</td>
</tr>
<tr>
<td>Functions</td>
<td>26.95 ± 26</td>
<td>33.4 ± 26.8</td>
</tr>
<tr>
<td>Global</td>
<td>26.69 ± 14.2</td>
<td>35.93 ± 14.1</td>
</tr>
</tbody>
</table>

One-way ANOVA for disease duration and global scores showed variance between groups with the p-value of 0.013 (Welch test 0.022 and Brown-Forsythe test 0.013). For symptom scale and emotion, the variance between groups showed the significance of 0.007 and 0.031, respectively. However, for the function scale, there was a non-significant group variance of 0.885. This showed that QOL was affected with prolonged disease duration and more so in emotions and symptoms domains.

ANOVA for marital status with global Skindex score showed the significance of 0.324 between groups (Welch 0.311 and Brown-Forsythe 0.275). Mean global scores were maximum for married. Significance between groups was 0.027 for symptom scale, 0.021 for emotion scale and 0.393 for function scale, respectively. This showed a significant relationship between marital status and symptom and emotion scale but not for Global and Function scale. For the emotion scale, more score was observed for unmarried and for the symptom scale, more score was observed for widowed.

Two-way ANOVA was used to estimate how the global score changed with the gender and disease severity. As the results were not statistically significant, a post hoc test was not applied. Significance of 0.120 showed equal error variance across groups. The p-value for gender was 0.001 and for severity 0.393. The p-value for the interaction between gender and severity was 0.006. There were significant p-values for the interaction between gender and severity in the case of global scores, symptom and emotion scale as shown in Table-II & III.

Pearson correlation for age with the global skindex-29 score was 0.051 with an insignificant p-value of 0.375. While Pearson correlation of age with symptom scale was 0.170 with the significant p-value of 0.003. Pearson correlation of age with emotion scale was - 0.225 (p-value of 0.001). Pearson correlation of age with function scale was 0.18 (p-value 0.002) as shown in the Table-IV.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Severity</th>
<th>Global Score</th>
<th>Symptom Score</th>
<th>Emotion Score</th>
<th>Function Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group 1 Male (n=150)</td>
<td>1 (n=19)</td>
<td>34.27 ± 12.4</td>
<td>16.5 ± 20</td>
<td>50.5 ± 32.6</td>
<td>35.7 ± 27</td>
</tr>
<tr>
<td></td>
<td>2 (n=45)</td>
<td>31.7 ± 14.2</td>
<td>16.5 ± 19.7</td>
<td>45.3 ± 30.7</td>
<td>33.3 ± 25</td>
</tr>
<tr>
<td></td>
<td>3 (n=38)</td>
<td>20.9 ± 12.6</td>
<td>12.3 ± 11</td>
<td>33 ± 24</td>
<td>17.3 ± 22</td>
</tr>
<tr>
<td></td>
<td>4 (n=31)</td>
<td>25.06 ± 14.5</td>
<td>11.6 ± 16</td>
<td>42.5 ± 30.8</td>
<td>20.9 ± 27</td>
</tr>
<tr>
<td></td>
<td>5 (n=9)</td>
<td>22.17 ± 8.7</td>
<td>9.5 ± 18</td>
<td>11 ± 19.8</td>
<td>45.6 ± 21.6</td>
</tr>
<tr>
<td></td>
<td>6 (n=6)</td>
<td>17.9 ± 15.8</td>
<td>28.6 ± 27</td>
<td>10 ± 13.4</td>
<td>14.9 ± 2.6</td>
</tr>
<tr>
<td></td>
<td>7 (n=2)</td>
<td>22.4 ± 14.2</td>
<td>25 ± 35</td>
<td>16 ± 15.9</td>
<td>26 ± 27.9</td>
</tr>
<tr>
<td>Group 2 Female (n=150)</td>
<td>1 (n=103)</td>
<td>34.6 ± 13.0</td>
<td>28.7 ± 24</td>
<td>43.8 ± 24</td>
<td>31 ± 26.9</td>
</tr>
<tr>
<td></td>
<td>2 (n=35)</td>
<td>38 ± 15.2</td>
<td>27.8 ± 22.5</td>
<td>47.5 ± 21</td>
<td>38.7 ± 27.3</td>
</tr>
<tr>
<td></td>
<td>3 (n=8)</td>
<td>43.6 ± 20.8</td>
<td>50 ± 30</td>
<td>48.4 ± 22</td>
<td>32.5 ± 28.8</td>
</tr>
<tr>
<td></td>
<td>4 (n=4)</td>
<td>35.5 ± 14</td>
<td>25 ± 20</td>
<td>38 ± 31.9</td>
<td>44 ± 5.2</td>
</tr>
<tr>
<td></td>
<td>5 (n=0)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>
In our study, disease duration was less than one year was in 84 (28%) patients, 1-5 years in 112 (37.3%) patients, 5-10 years in 68 (22.7%), >10 years in 36 (12%) patients. Results were comparable to a Korean study which showed 26.5% had a disease duration of less than 1 year, 43.3% had 1-5 years and 30.2% patients had the disease duration of >5 years.20

We categorized the severity of AGA in our male patients by using Norwood’s classification and Sinclair’s classification for females. In other studies, patients were classified as suffering from mild or severe disease based on the BSAP scale.21,22 About 60.1% had mild disease and 39.9% had severe diseases. Ludwig’s classification was used for females and Hamilton’s classification for male patients in a Turkish study.23

EFA done in our study yielded three principal components of the questionnaire i.e., emotion, symptom and function. This was consistent with the findings of Chren et al, who initially made and then checked the psychometric properties of Skindex-29.2

Our study showed a significant effect of gender (p=0.0001) on global scores, symptom scale (p=0.0001), emotion scale (p=0.05), function scale (p=0.035), which were more in females than in males. Another study in Riyadh showed comparable results i.e., more scores in females using DLQI (Dermatology life quality index) and more willing to pay for the treatment.24 Similarly, in a Spanish study, for women with alopecia highest scores were observed in the emotional domain.25 This showed that women are more affected emotionally and have impaired quality of life because of FPHL as compared to men.

In a study by Guerra Tapia et al, scores increased with the grade of alopecia, especially in the emotion domain and were maximum in Sinclair grade II.25 Our results showed no significant effect of the grade of AGA on Skindex scores. Similarly, age with global scores had a positive correlation with symptom and function scale and negative correlation with emotion scale (p>0.05).

Skindex-29 (Hair-specific) in English is a reliable tool to assess the impact of AGA/FPHL on QOL in our population. AGA/FPHL significantly affects the QOL in females more than males and people with longer disease duration.

**CONCLUSION**

Skindex-29 can be successfully used in our setup for quality of life studies in AGA/FPHL patients. Females were more severely affected than males as per global scores on Skindex-29.
Conflict of Interest: None.

Authors’ Contribution


REFERENCES